肠道微生物群和血液代谢物与儿童肥胖之间的因果关系:孟德尔的随机化研究
Ji-Gan Wang1, Xiu-Hua Pan2, Yan Li2
1Department of Pediatrics, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region; Guangxi Clinical Research Center for Pediatric Diseases, Nanning, China. wangjigan@163.com.
Pediatric research
|September 25, 2025
概括
这项研究揭示了特定的肠道细菌和血液代谢产物与儿童肥胖有因果关系. 一些细菌和代谢产物可以防止肥胖,而另一些则会增加风险,提供新的干预目标.
科学领域:
- 微生物组研究的研究.
- 代谢学 代谢学 代谢学
- 儿科卫生保健 儿科卫生保健
背景情况:
- 儿童肥胖是一个日益严重的全球健康问题.
- 人们越来越多地认识到肠道微生物群在肥胖中的作用,但尚未完全理解.
- 血液代谢物可能会调解肠道微生物群与肥胖的联系.
研究的目的:
- 调查肠道微生物群和儿童肥胖之间的因果关系.
- 探索血液代谢物在这种关联中的调解作用.
- 为了确定儿童肥胖的潜在治疗点.
主要方法:
- 双向的双样本孟德尔随机化分析.
- 利用了473种肠道微生物群和1400种代谢物的数据.
- 逆变量为因果推理的加权方法.
主要成果:
- 确定了12种与儿童肥胖 (7种保护性,5种风险因素) 相关的肠道微生物群.
- 发现了与儿童肥胖相关的18种代谢物 (6种保护性,12种风险因素).
- 发现了10个重要的调解途径,包括阿德雷纳酸和X-12830.
结论:
- 提供了关于肠道微生物群和代谢物的因果作用在儿童肥胖症中的新证据.
- 突出了干预的特定微生物和代谢目标.
- 暗示了针对肠-宿主-代谢轴的个性化治疗策略的潜力.
相关概念视频
Anatomy of the Intestines
86.8K
Although digestion of proteins, carbohydrates, and lipids may begin in the stomach, it is completed in the intestine. The absorption of nutrients, water, and electrolytes from food and drink also occurs in the intestine. The intestines can be divided into two structurally distinct organs—the small and large intestines.
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
86.8K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
247
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
247
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169


